{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:50Z","timestamp":1791305150064,"version":"4.3.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002382","name":"King Faisal Specialist Hospital and Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to assess the feasibility of bendamustine as an alternative to BCNU. We compared 71 patients who received either bendamustine (Benda-EAM group) or BCNU (BEAM group) conditioning. Considering previous reports of increased cardiotoxicity, nephrotoxicity, and mucositis, we adopted a lower bendamustine dose of 160 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day administered for 2 days. There was no increase in nephrotoxicity and cardiotoxicity. Further, positive results were also obtained for neutrophil and platelet engraftment, appearing earlier in patients treated with Benda-EAM (10 vs. 14 days and 16 vs. 27 days, respectively). However, caution is warranted because an increased frequency of Grade 3 mucositis was observed in the Benda-EAM group (82.4% vs. 48%). This was accompanied by an increased need for parenteral nutrition. Despite the lower dose of bendamustine, the overall and progression-free survival rates were comparable between the Benda-EAM and BEAM groups. In conclusion, a lower dose of ben- damustine may be an attractive alternative to BCNU as a tolerable treatment modality for patients with relapsed\/refractory lymphoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T12:03:30Z","timestamp":1606219410000},"page":"327-335","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma"],"prefix":"10.4103","volume":"14","author":[{"given":"Naif I.","family":"AlJohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momen","family":"Nasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalil","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayed","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassim","family":"Albeirouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241211","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"R2-7-20241211","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-7-20241211","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0277-5379(90)90180-2","article-title":"BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin\u2019s lymphomas","volume":"26","author":"Colombat","year":"1990","journal-title":"Eur J Cancer"},{"key":"R4-7-20241211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/bmt.2015.273","article-title":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT","volume":"51","author":"Sellner","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R5-7-20241211","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","article-title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","volume":"57","author":"Isidori","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R6-7-20241211","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1702154","article-title":"Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies","volume":"25","author":"Alessandrino","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R7-7-20241211","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2165\/11209510-000000000-00000","article-title":"Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin\u2019s lymphoma and multiple myeloma","volume":"72","author":"Hoy","year":"2012","journal-title":"Drugs"},{"key":"R8-7-20241211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5045\/br.2019.54.2.108","article-title":"Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed\/refractory lymphoma","volume":"54","author":"Shabbir-Moosajee","year":"2019","journal-title":"Blood Res"},{"key":"R9-7-20241211","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"Am J Hematol"},{"key":"R10-7-20241211","first-page":"113","article-title":"Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation","volume":"22","author":"Frankiewicz","year":"2018","journal-title":"Contemp Oncol (Pozn"},{"key":"R11-7-20241211","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R12-7-20241211","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00277-016-2900-y","article-title":"BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients","volume":"96","author":"Gilli","year":"2017","journal-title":"Ann Hematol"},{"key":"R13-7-20241211","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"R14-7-20241211","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41409-020-0783-y","article-title":"Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers","volume":"55","author":"Hueso","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R15-7-20241211","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/s41409-019-0508-2","article-title":"High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients","volume":"54","author":"Prediletto","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R16-7-20241211","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41409-018-0328-9","article-title":"High-dose Benda-EAM versus BEAM in patients with relapsed\/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"54","author":"Tsang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R17-7-20241211","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/10428194.2017.1403019","article-title":"A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience","volume":"59","author":"Saleh","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.11.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:55Z","timestamp":1787838595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.11.003"}},"subtitle":["A retrospective single-center study"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.11.003","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}